Endurance / Stamina

MOTS-c evidence derives almost entirely from animal models (mice). CohBar, the primary company pursuing clinical development, dissolved before completing trials. Existing human biomarker studies demonstrate correlations between endogenous MOTS-c levels and metabolic outcomes but do not establish supplementation efficacy.

Implications: Without human clinical trials, no claims about MOTS-c supplementation improving endurance or stamina in humans can be substantiated. Translating rodent exercise-capacity findings to human performance remains speculative.

No formal toxicology or long-term safety studies exist for MOTS-c or related mitochondrial-derived peptides in humans. Anecdotal reports from self-experimenters cite elevated heart rate, palpitations, and insomnia, but these are uncontrolled observations. GW501516 carcinogenicity data in rodents does not clarify risk profiles for other PPAR-delta agonists or mitochondrial peptides.

Implications: Absence of safety data makes risk-benefit analysis impossible. Anecdotal adverse effects cannot be attributed or ruled out without controlled studies, leaving users and practitioners without guidance on contraindications or monitoring.

The mechanism by which MOTS-c enters target cells without degradation is poorly understood. The peptide is extremely unstable with a reported half-life of only 1-2 hours. No reliable delivery systems exist to protect the peptide from proteolysis or direct it to specific tissues such as skeletal muscle or mitochondria.

Implications: Even if MOTS-c proves efficacious, current delivery limitations may render exogenous administration impractical. Bioavailability challenges undermine any dosing protocol and make outcome measurement unreliable.

Human dosing for MOTS-c has not been established through any formal dose-finding study. The potential interaction between MOTS-c and Metformin, both of which modulate AMPK signaling, remains unverified in human subjects despite overlapping mechanistic pathways.

Implications: Without established dosing, any self-administration carries unknown risk. Potential synergistic or antagonistic interactions with common metabolic drugs like Metformin could produce unexpected effects in the populations most likely to use these compounds.

Products marketed as 'mito organelles' extracts have poorly defined molecular identities. No public standards exist for extraction methods, batch-to-batch consistency, or quality markers. These products occupy a regulatory grey zone with no established framework for oversight or claims verification.

Implications: Consumers cannot verify what they are purchasing or whether products contain active compounds at meaningful concentrations. The lack of standardization and regulatory clarity creates both safety risks and barriers to legitimate research.